{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T07:29:51Z","timestamp":1790926191901,"version":"4.1.0"},"reference-count":172,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2004,1,1]],"date-time":"2004-01-01T00:00:00Z","timestamp":1072915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,1,1]],"date-time":"2004-01-01T00:00:00Z","timestamp":1072915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2004,1]]},"DOI":"10.1016\/j.biopha.2003.11.003","type":"journal-article","created":{"date-parts":[[2003,12,19]],"date-time":"2003-12-19T05:57:50Z","timestamp":1071813470000},"page":"24-38","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":141,"title":["Serum tumor markers in the management of ovarian, endometrial and cervical cancer"],"prefix":"10.1016","volume":"58","author":[{"given":"Angiolo","family":"Gadducci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Cosio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Carpi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Nicolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea Riccardo","family":"Genazzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2003.11.003_BIB1","first-page":"75","article-title":"Tumor markers: definition and classification","author":"Ballesta","year":"1993"},{"key":"10.1016\/j.biopha.2003.11.003_BIB2","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/00004347-198303000-00005","article-title":"Tissue distribution of a coelomic epithelium-related antigen recognized by the monoclonal antibody OC125","volume":"2","author":"Kabawat","year":"1983","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/oxfordjournals.humrep.a136832","article-title":"The CA 125\u00a0tumour-associated antigen: a review of the literature","volume":"4","author":"Jacobs","year":"1989","journal-title":"Hum Reprod"},{"key":"10.1016\/j.biopha.2003.11.003_BIB4","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1177\/172460089801300402","article-title":"CA 125: the past and the future","volume":"13","author":"Bast","year":"1998","journal-title":"Int J Biol Markers"},{"key":"10.1016\/j.biopha.2003.11.003_BIB5","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1002\/1097-0142(19951115)76:10+<2092::AID-CNCR2820761331>3.0.CO;2-T","article-title":"Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection","volume":"76","author":"Berek","year":"1995","journal-title":"Cancer"},{"key":"10.1016\/j.biopha.2003.11.003_BIB6","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0090-8258(92)90030-M","article-title":"The concomitant determination of different tumor markers in patients with epithelial ovarian cancer and benign ovarian masses: relevance for differential diagnosis","volume":"44","author":"Gadducci","year":"1992","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB7","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1006\/gyno.1994.1179","article-title":"Prospective multicenter study on CA 125\u00a0in postmenopausal pelvic masses","volume":"54","author":"Maggino","year":"1994","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB8","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1002\/1097-0142(19940815)74:4<1398::AID-CNCR2820740433>3.0.CO;2-J","article-title":"Diagnostic value of pelvic examination, ultrasound, and serum CA 125\u00a0in postmenopausal women with a pelvic mass. An international multicenter study","volume":"74","author":"Schutter","year":"1994","journal-title":"Cancer"},{"key":"10.1016\/j.biopha.2003.11.003_BIB9","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0090-8258(92)90031-D","article-title":"The concomitant determination of different serum tumor markers in epithelial ovarian cancer: relevance for monitoring the response to chemotherapy and follow-up of patients","volume":"44","author":"Fioretti","year":"1992","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB10","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1006\/gyno.1995.1181","article-title":"Serum half-life of CA 125\u00a0during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study","volume":"58","author":"Gadducci","year":"1995","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB11","first-page":"1535","article-title":"Role of tumour markers in monitoring epithelial ovarian cancer","volume":"182","author":"Meyer","year":"2000","journal-title":"Br J Cancer"},{"key":"10.1016\/j.biopha.2003.11.003_BIB12","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1136\/bmj.306.6884.1030","article-title":"Prevalence screening for ovarian cancer in postmenopausal women by CA 125\u00a0measurement and ultrasonography","volume":"306","author":"Jacobs","year":"1993","journal-title":"Br Med J"},{"key":"10.1016\/j.biopha.2003.11.003_BIB13","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1136\/bmj.313.7069.1355","article-title":"Risk of diagnosis of ovarian cancer after raised serum CA 125\u00a0concentration: a prospective cohort study","volume":"313","author":"Jacobs","year":"1996","journal-title":"Br Med J"},{"key":"10.1016\/j.biopha.2003.11.003_BIB14","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1038\/sj.bjc.6690575","article-title":"Ultrasound assessment of ovarian cancer risk in postmenopausal women with CA125 elevation","volume":"80","author":"Menon","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1016\/j.biopha.2003.11.003_BIB15","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1471-0528.2000.tb11685.x","article-title":"Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening","volume":"107","author":"Menon","year":"2000","journal-title":"Br J Obstet Gynaecol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB16","first-page":"249","article-title":"Preoperative serum tumor-associated antigen levels in women with pelvic masses","volume":"75","author":"Soper","year":"1990","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB17","first-page":"206","article-title":"Serum CA 125\u00a0and other tumor markers in ovarian cancer","author":"Gadducci","year":"2001"},{"key":"10.1016\/j.biopha.2003.11.003_BIB18","first-page":"252","article-title":"The combined evaluation of ultrasound, serum CA 125\u00a0assay and serum CA 19-9 assay in discriminating a benign from a malignant ovarian mass","volume":"3","author":"Gadducci","year":"1990","journal-title":"Cancer J"},{"key":"10.1016\/j.biopha.2003.11.003_BIB19","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1006\/gyno.1996.0098","article-title":"Differential diagnosis of adnexal masses with transvaginal sonography, color flow imaging, and serum CA 125\u00a0assay in pre- and postmenopausal women","volume":"61","author":"Strigini","year":"1996","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB20","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/j.1471-0528.1999.tb08318.x","article-title":"Comparison of two malignancy risk indices based on serum CA125, ultrasound score and menopausal status in the diagnosis of ovarian masses","volume":"106","author":"Morgante","year":"1999","journal-title":"Br J Obstet Gynaecol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB21","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0002-9378(99)70436-9","article-title":"A comparison of methods for preoperative discrimination between malignant and benign adnexal masses: the development of a new logistic regression model","volume":"181","author":"Timmerman","year":"1999","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB22","first-page":"75","article-title":"Prospective evaluation of logistic regression models for the diagnosis of ovarian cancer","volume":"96","author":"Aslam","year":"2000","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB23","first-page":"251","article-title":"Evaluation of CA 125\u00a0as a prognostic and predictive factor in ovarian cancer","volume":"3","author":"Mobus","year":"1988","journal-title":"J Tumor Marker Oncol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB24","first-page":"140","article-title":"Relationship of preoperative serum CA-125 to survival in epithelial ovarian carcinoma","volume":"41","author":"Geisler","year":"1996","journal-title":"J Reprod Med"},{"key":"10.1016\/j.biopha.2003.11.003_BIB25","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1159\/000010062","article-title":"Preoperative determination of several tumor markers in patients with primary epithelial ovarian carcinoma","volume":"47","author":"Kudoh","year":"1999","journal-title":"Gynecol Obstet Invest"},{"key":"10.1016\/j.biopha.2003.11.003_BIB26","first-page":"1002","article-title":"Prognostic value of pre- and postoperative serum CA 125\u00a0levels in ovarian cancer: new aspects and multivariate analysis","volume":"79","author":"Makar","year":"1992","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB27","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1177\/172460080001500204","article-title":"Prognostic value of CA125 kinetics and half-life in advanced ovarian cancer","volume":"15","author":"Colakovic","year":"2000","journal-title":"Int J Biol Markers"},{"key":"10.1016\/j.biopha.2003.11.003_BIB28","first-page":"29","article-title":"The decline of CA 125\u00a0level after surgery reflects the size of residual ovarian cancer","volume":"81","author":"Brand","year":"1993","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB29","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S0959-8049(05)80203-5","article-title":"CA 125\u00a0serum levels in the early post-operative period do not reflect tumour reduction obtained by cytoreductive surgery","volume":"29A","author":"Yedema","year":"1993","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.biopha.2003.11.003_BIB30","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1006\/gyno.1996.0312","article-title":"The relationship between postoperative decline of serum CA 125\u00a0levels and size of residual disease after initial surgery in patients with advanced ovarian cancer: a CTF study","volume":"63","author":"Gadducci","year":"1996","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB31","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0090-8258(88)90244-2","article-title":"Ovarian cancer: the prognostic value of the serum half-life of CA125 during induction chemotherapy","volume":"30","author":"van der Burg","year":"1988","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB32","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1006\/gyno.2000.5982","article-title":"Prognostic significance of CA 125\u00a0and TPS levels after three chemotherapy courses in ovarian cancer patients","volume":"79","author":"van Dalen","year":"2000","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB33","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/0002-9378(84)90035-8","article-title":"Monitoring human ovarian carcinoma with a combination of CA 125, CA 19-9 and carcinoembryonic antigen","volume":"149","author":"Bast","year":"1984","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB34","first-page":"1660","article-title":"Serum measurements of CA 125, CA 19.9, CA 15.3, and TAG-72 in patients with epithelial ovarian cancer","volume":"13","author":"Gadducci","year":"1993","journal-title":"Anticancer Res"},{"key":"10.1016\/j.biopha.2003.11.003_BIB35","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/oxfordjournals.annonc.a010602","article-title":"Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group study","volume":"7","author":"Rustin","year":"1996","journal-title":"Ann Oncol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB36","first-page":"301","article-title":"Serum CA125 assay in the early diagnosis of recurrent epithelial ovarian cancer: a CTF study","volume":"3","author":"Gadducci","year":"1996","journal-title":"Oncol Rep"},{"key":"10.1016\/j.biopha.2003.11.003_BIB37","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1006\/gyno.2000.5787","article-title":"Declining CA-125 in an ovarian cancer patient with progression of measurable disease: a rational hypothesis for discordant results","volume":"77","author":"Markman","year":"2000","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB38","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1200\/JCO.2000.18.8.1733","article-title":"Selection of active drugs for ovarian cancer based on CA-125 and standard response rates in phase II trials","volume":"18","author":"Rustin","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB39","first-page":"1069","article-title":"Prospective multicenter study on the clinical utility of CA 72.4\u00a0in postmenopausal patients with pelvic masses","volume":"2","author":"Maggino","year":"1995","journal-title":"Oncol Rep"},{"key":"10.1016\/j.biopha.2003.11.003_BIB40","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/BF01542654","article-title":"Colorectal carcinoma antigens detected by hybridoma antibodies","volume":"5","author":"Koprowski","year":"1979","journal-title":"Somatic Cell Genet"},{"key":"10.1016\/j.biopha.2003.11.003_BIB41","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1089\/hyb.1984.3.223","article-title":"Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumor","volume":"3","author":"Kufe","year":"1984","journal-title":"Hybridoma"},{"key":"10.1016\/j.biopha.2003.11.003_BIB42","first-page":"2582","article-title":"MAM-6 antigen, a new serum marker for breast cancer monitoring","volume":"46","author":"Hilkens","year":"1986","journal-title":"Cancer Res"},{"key":"10.1016\/j.biopha.2003.11.003_BIB43","first-page":"995","article-title":"Tumor associated glycoprotein (TAG-72) in ovarian carcinomas defined by monoclonal antibody B72-3","volume":"76","author":"Thor","year":"1986","journal-title":"Int J Natl Cancer Inst"},{"key":"10.1016\/j.biopha.2003.11.003_BIB44","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/ijc.2910370504","article-title":"A radioimmunoassay for the detection of a human tumor-associated glycoprotein (TAG-72) using monoclonal antibody B72-3","volume":"37","author":"Paterson","year":"1986","journal-title":"Int J Cancer"},{"key":"10.1016\/j.biopha.2003.11.003_BIB45","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0303-7207(02)00060-6","article-title":"Inhibins\/activins as diagnostic markers for ovarian cancer","volume":"191","author":"Robertson","year":"2002","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB46","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1056\/NEJM199311183292104","article-title":"Elevated serum inhibin concentrations in postmenopausal women with ovarian tumors","volume":"329","author":"Healy","year":"1993","journal-title":"New Engl J Med"},{"key":"10.1016\/j.biopha.2003.11.003_BIB47","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/clinchem\/45.5.651","article-title":"Combined inhibin and CA125 assays in the detection of ovarian cancer","volume":"45","author":"Robertson","year":"1999","journal-title":"Clin Chem"},{"key":"10.1016\/j.biopha.2003.11.003_BIB48","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/(SICI)1097-0142(19990115)85:2<465::AID-CNCR26>3.0.CO;2-W","article-title":"Preoperative serum levels of inhibin A is an independent prognostic factor for the survival of postmenopausal women with epithelial ovarian carcinoma","volume":"85","author":"Frias","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.biopha.2003.11.003_BIB49","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/0002-9378(91)90582-C","article-title":"Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer","volume":"164","author":"Berek","year":"1991","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB50","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/bjc.1995.71","article-title":"Prognostic significance of interleukin 6\u00a0serum levels in patients with ovarian cancer","volume":"71","author":"Scambia","year":"1995","journal-title":"Br J Cancer"},{"key":"10.1016\/j.biopha.2003.11.003_BIB51","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1006\/gyno.1997.4726","article-title":"Serum evaluation of interleukin 6\u00a0in ovarian cancer patients","volume":"66","author":"Tempfer","year":"1997","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB52","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1159\/000012033","article-title":"IL-6, M-CFS and IAP cytokines in ovarian cancer: simultaneous assessment of serum levels","volume":"57","author":"Foti","year":"1999","journal-title":"Oncology"},{"key":"10.1016\/j.biopha.2003.11.003_BIB53","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1006\/gyno.1998.4259","article-title":"Serum macrophage colony-stimulating factor (M-CSF) levels in patients with epithelial ovarian cancer","volume":"70","author":"Gadducci","year":"1998","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB54","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1093\/jnci\/85.21.1748","article-title":"Elevation of multiple serum markers in patients with stage I ovarian cancer","volume":"85","author":"Woolas","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.biopha.2003.11.003_BIB55","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1002\/1097-0142(20011201)92:11<2837::AID-CNCR10093>3.0.CO;2-5","article-title":"OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal","volume":"92","author":"van Haaften-Day","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.biopha.2003.11.003_BIB56","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/S0002-9378(96)70113-8","article-title":"Prognostic role of immunosuppressive acidic protein in advanced ovarian cancer","volume":"175","author":"Scambia","year":"1996","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB57","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1200\/JCO.1993.11.8.1506","article-title":"OVX1 radioimmunoassay complements CA-125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance procedures","volume":"11","author":"Xu","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB58","first-page":"3576","article-title":"Serum soluble fas level as a prognostic factor in patients with gynecological malignancies","volume":"6","author":"Konno","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.biopha.2003.11.003_BIB59","first-page":"277","article-title":"The clinical relevance of serum CYFRA 21-1 assay in patients with ovarian cancer","volume":"11","author":"Gadducci","year":"2001","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.biopha.2003.11.003_BIB60","first-page":"360","article-title":"Vascular endothelial growth factor serum concentration in ovarian cancer","volume":"92","author":"Tempfer","year":"1998","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB61","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1006\/gyno.1999.5418","article-title":"Serum vascular endothelial growth factor in epithelial ovarian neoplasms: correlation with patient survival","volume":"74","author":"Chen","year":"1999","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB62","first-page":"1401","article-title":"Serum preoperative vascular endothelial growth factor (VEGF) in epithelial ovarian cancer: relationship with prognostic variables and clinical outcome","volume":"19","author":"Gadducci","year":"1999","journal-title":"Anticancer Res"},{"key":"10.1016\/j.biopha.2003.11.003_BIB63","first-page":"5109","article-title":"Prognostic relevance of serum vascular endothelial growth factor in ovarian cancer","volume":"20","author":"Oehler","year":"2000","journal-title":"Anticancer Res"},{"key":"10.1016\/j.biopha.2003.11.003_BIB64","first-page":"3193","article-title":"Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer","volume":"8","author":"Cooper","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.biopha.2003.11.003_BIB65","first-page":"181","article-title":"Clinical significance of vascular endothelial growth factor in sera of patients with gynaecological malignant tumors","volume":"21","author":"Peng","year":"2002","journal-title":"Ai Zheng"},{"key":"10.1016\/j.biopha.2003.11.003_BIB66","first-page":"807","article-title":"The serum concentration of human kallikrein 10\u00a0represents a novel biomarker for ovarian cancer diagnosis and prognosis","volume":"63","author":"Luo","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.biopha.2003.11.003_BIB67","first-page":"599","article-title":"Cytokeratins of normal epithelia and some neoplasms of the female genital tract","volume":"49","author":"Moll","year":"1983","journal-title":"Lab Invest"},{"key":"10.1016\/j.biopha.2003.11.003_BIB68","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1159\/000217891","article-title":"From tissue polypeptide antigen to specific cytokeratin assays","volume":"15","author":"Bormer","year":"1994","journal-title":"Tumour Biol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB69","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/gyno.1995.1071","article-title":"Cytokeratin subunit 19\u00a0measured by CYFRA 21-1 assay in the follow-up of cervical cancer","volume":"56","author":"Kainz","year":"1995","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB70","first-page":"966","article-title":"Enzymun-test Cyfra 21-1: a new marker for NSCLC","volume":"38","author":"Bodenmuller","year":"1992","journal-title":"Clin Chem"},{"key":"10.1016\/j.biopha.2003.11.003_BIB71","first-page":"1841","article-title":"Serum CYFRA 21-1 assay in squamous cell carcinoma of the cervix","volume":"13","author":"Ferdeghini","year":"1993","journal-title":"Anticancer Res"},{"key":"10.1016\/j.biopha.2003.11.003_BIB72","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1006\/gyno.1994.1309","article-title":"Prognostic significance of serum fragments of cytokeratin 19\u00a0measured by Cyfra 21-1 in cervical cancer","volume":"55","author":"Bonfrer","year":"1994","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB73","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/1097-0142(19950901)76:5<807::AID-CNCR2820760515>3.0.CO;2-M","article-title":"Clinical value of pretreatment serum Cyfra 21-1, tissue polypeptide antigen, and squamous cell carcinoma antigen levels in patients with cervical cancer","volume":"76","author":"Gaarenstroom","year":"1995","journal-title":"Cancer"},{"key":"10.1016\/j.biopha.2003.11.003_BIB74","first-page":"55","article-title":"The clinical value of SCC antigen in cancer of the uterine cervix","author":"de Bruijn","year":"1997"},{"key":"10.1016\/j.biopha.2003.11.003_BIB75","first-page":"50","article-title":"Cancer of the uterine cervix: sensitivity and specificity of serum CYFRA 21.1\u00a0determinations","volume":"19","author":"Callet","year":"1998","journal-title":"Eur J Gynaecol Oncol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB76","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0955-2235(94)90019-1","article-title":"Vascular endothelial growth factor and its receptors","volume":"5","author":"Neufeld","year":"1994","journal-title":"Progr Growth Factor Res"},{"key":"10.1016\/j.biopha.2003.11.003_BIB77","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1111\/j.1349-7006.1996.tb02127.x","article-title":"Inhibition of growth and metastasis of ovarian carcinoma by administering a drug capable of interfering with vascular endothelial growth factor activity","volume":"87","author":"Mu","year":"1996","journal-title":"Jpn J Cancer Res"},{"key":"10.1016\/j.biopha.2003.11.003_BIB78","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1093\/jnci\/87.7.506","article-title":"Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma","volume":"87","author":"Boocock","year":"1995","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.biopha.2003.11.003_BIB79","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3109\/09513599609023600","article-title":"Vascular endothelial growth factor messenger ribonucleic acid expression in human ovarian and endometrial cancer","volume":"10","author":"Doldi","year":"1996","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB80","first-page":"621","article-title":"Association of vascular endothelial growth factor expression with tumor cell proliferation in ovarian carcinoma","volume":"17","author":"Mattern","year":"1997","journal-title":"Anticancer Res"},{"key":"10.1016\/j.biopha.2003.11.003_BIB81","first-page":"821","article-title":"Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients","volume":"2","author":"Yamamoto","year":"1996","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.biopha.2003.11.003_BIB82","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/(SICI)1097-0142(19990101)85:1<178::AID-CNCR25>3.0.CO;2-7","article-title":"Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease","volume":"85","author":"Kraft","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.biopha.2003.11.003_BIB83","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/0090-8258(90)90425-K","article-title":"Alpha-fetoprotein in malignant germ cell tumors of the ovary","volume":"39","author":"Kawai","year":"1990","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB84","first-page":"849","article-title":"Germ cell tumors of the ovary","author":"Talerman","year":"1994"},{"key":"10.1016\/j.biopha.2003.11.003_BIB85","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/0090-8258(92)90486-3","article-title":"Ovarian germ cell malignancies: the Yale University experience","volume":"45","author":"Schwartz","year":"1992","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB86","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0002-9378(99)70561-2","article-title":"Surgical resection alone is effective treatment for ovarian immature teratoma in children and adolescents: a report of the Pediatric Oncology Group and the Children\u2019s Cancer Group","volume":"181","author":"Cushing","year":"1999","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB87","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0022-3468(96)90090-1","article-title":"Endodermal sinus tumor in children","volume":"31","author":"Davidoff","year":"1996","journal-title":"J Pediatr Surg"},{"key":"10.1016\/j.biopha.2003.11.003_BIB88","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1006\/gyno.1998.5006","article-title":"Ovarian mixed germ cell tumor composed of polyembryoma and immature teratoma","volume":"69","author":"Takemori","year":"1998","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB89","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1006\/gyno.2001.6541","article-title":"Tumor chemoconversion following surgery, chemotherapy, and normalization of serum tumor markers in a woman with a mixed type germ cell ovarian tumor","volume":"84","author":"David","year":"2002","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB90","doi-asserted-by":"crossref","first-page":"244","DOI":"10.12968\/hosp.2002.63.4.2048","article-title":"Elevated alpha-fetoprotein levels in a woman with ovarian teratoma","volume":"63","author":"Huang","year":"2002","journal-title":"Hosp Med"},{"key":"10.1016\/j.biopha.2003.11.003_BIB91","first-page":"355","article-title":"Surgery of germ cell tumours of the ovary","volume":"10","author":"Schwartz","year":"2000","journal-title":"Forum"},{"key":"10.1016\/j.biopha.2003.11.003_BIB92","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1006\/gyno.2000.5784","article-title":"Clinical significance of combined use of macrophage colony-stimulating factor and squamous cell carcinoma antigen as selective diagnostic marker for squamous cell carcinoma arising in mature cystic teratoma of the ovary","volume":"77","author":"Suzuki","year":"2000","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB93","first-page":"511","article-title":"Serum lactic dehydrogenase: a tumor marker for dysgerminoma","volume":"72","author":"Schwartz","year":"1988","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB94","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/0090-8258(88)90044-3","article-title":"Lactic dehydrogenase, alkaline phosphatase and human chorionic gonadotropin in a pure ovarian dysgerminoma","volume":"30","author":"Dgani","year":"1988","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB95","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0090-8258(92)90058-Q","article-title":"Serum lactic dehydrogenase as a tumor marker in dysgerminoma","volume":"44","author":"Pressley","year":"1992","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB96","first-page":"212","article-title":"LDH and LDH isoenzymes in ovarian dysgerminoma","volume":"16","author":"Levato","year":"1995","journal-title":"Eur J Gynaecol Oncol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB97","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0301-2115(98)00162-6","article-title":"Ovarian dysgerminoma showing high serum levels and positive immunostaining of placental alcaline phosphatase and neuron-specific enolase associated with elevation of serum prolactin level","volume":"81","author":"Yoshida","year":"1998","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB98","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S0046-8177(97)90056-3","article-title":"Immunohistochemical staining of ovarian granulosa cell tumors with monoclonal antibody against inhibin","volume":"28","author":"McCluggage","year":"1997","journal-title":"Hum Pathol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB99","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/S0002-9378(97)70090-5","article-title":"Production of inhibin A and inhibin B in human ovarian sex cord stromal tumors","volume":"177","author":"Yamashita","year":"1997","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB100","first-page":"187","article-title":"Is potential to produce inhibins related to prognosis in ovarian granulosa cell tumors?","volume":"21","author":"Ala-Fossi","year":"2000","journal-title":"Eur J Gynaecol Oncol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB101","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1006\/gyno.1996.4520","article-title":"Serum inhibin and disease status in women with ovarian granulosa cell tumors","volume":"64","author":"Boggess","year":"1997","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB102","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/00001703-200302000-00005","article-title":"Update of granulosa cell tumours of the ovary","volume":"15","author":"Stuart","year":"2003","journal-title":"Curr Opin Obstet Gynecol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB103","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1200\/JCO.2003.10.019","article-title":"Granulosa cell tumor of the ovary","volume":"21","author":"Schumer","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB104","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1006\/gyno.1994.1213","article-title":"Combined use of CA 125\u00a0and CA 15-3 in patients with endometrial carcinoma","volume":"54","author":"Scambia","year":"1994","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB105","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/0002-9378(95)90178-7","article-title":"Macrophage colony-stimulating factor 1, a clinically useful tumor marker in endometrial adenocarcinoma: comparison with CA 125\u00a0and the aminoterminal propeptide of type III procollagen","volume":"173","author":"Hakala","year":"1995","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB106","first-page":"4635","article-title":"TATI (tumor associated trypsin inhibitor) and cancer antigen 125 (CA 125) in patients with early-stage endometrial cancer","volume":"18","author":"Peters-Engl","year":"1998","journal-title":"Anticancer Res"},{"key":"10.1016\/j.biopha.2003.11.003_BIB107","first-page":"315","article-title":"The value of serum CA 125\u00a0and the association CA 125\/CA 19-9 in endometrial carcinoma","volume":"20","author":"Cherchi","year":"1999","journal-title":"Eur J Gynaecol Oncol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB108","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1136\/ijgc-00009577-200207000-00007","article-title":"Tissue and serum CA125 expression in endometrial cancer","volume":"12","author":"Ginath","year":"2002","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.biopha.2003.11.003_BIB109","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1006\/gyno.1996.4545","article-title":"Significance of a single CA 125\u00a0assay combined with ultrasound in the early detection of ovarian and endometrial cancer","volume":"64","author":"Vuento","year":"1997","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB110","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/S0002-9378(96)70678-6","article-title":"Preoperative evaluation of macrophage colony-stimulating factor levels in patients with endometrial cancer","volume":"174","author":"Olt","year":"1996","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB111","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0029-7844(97)00286-X","article-title":"Value of preoperative CA 125\u00a0level in the management of uterine cancer and prediction of clinical outcome","volume":"90","author":"Sood","year":"1997","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB112","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1006\/gyno.1997.4620","article-title":"Is OVX1 a suitable marker for endometrial cancer?","volume":"65","author":"Beck","year":"1997","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB113","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1006\/gyno.2002.6664","article-title":"Can a preoperative CA 125\u00a0level be a criterion for full pelvic lymphadenectomy in surgical staging of endometrial cancer?","volume":"86","author":"Hsieh","year":"2002","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB114","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1006\/gyno.1998.5018","article-title":"Determination of a normal level of serum CA 125\u00a0in postmenopausal women as a tool for preoperative evaluation and postoperative surveillance of endometrial carcinoma","volume":"69","author":"Kurihara","year":"1998","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB115","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1046\/j.1469-0705.1999.14030210.x","article-title":"Comparative study of transvaginal ultrasonography and CA 125\u00a0in the preoperative evaluation of myometrial invasion in endometrial carcinoma","volume":"14","author":"Alcazar","year":"1999","journal-title":"Ultrasound Obstet Gynecol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB116","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0304-3835(97)00332-7","article-title":"An evaluation of CA125 levels in 291\u00a0normal postmenopausal and 20\u00a0endometrial adenocarcinoma-bearing women before and after surgery","volume":"121","author":"Takami","year":"1997","journal-title":"Cancer Lett"},{"key":"10.1016\/j.biopha.2003.11.003_BIB117","first-page":"1897","article-title":"Serum CA125 measurements to identify patients with endometrial cancer who require lymphadenectomy","volume":"18","author":"Koper","year":"1998","journal-title":"Anticancer Res"},{"key":"10.1016\/j.biopha.2003.11.003_BIB118","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1067\/mob.2000.106251","article-title":"Preoperative CA 125\u00a0in endometrial cancer: is it useful?","volume":"182","author":"Dotters","year":"2000","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB119","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1046\/j.1525-1500.1999.99043.x","article-title":"Role of serial tumor markers in the surveillance for recurrence in endometrial cancer","volume":"23","author":"Lo","year":"1999","journal-title":"Cancer Detect Prev"},{"key":"10.1016\/j.biopha.2003.11.003_BIB120","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1006\/gyno.1996.0331","article-title":"Radiation-induced CA 125\u00a0production by mesothelial cells","volume":"63","author":"Carpenter","year":"1996","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB121","first-page":"3903","article-title":"Serum tetranectin and CA125 in endometrial adenocarcinoma","volume":"20","author":"Lundstrom","year":"2000","journal-title":"Anticancer Res"},{"key":"10.1016\/j.biopha.2003.11.003_BIB122","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1159\/000218037","article-title":"Prognostic significance of tumour markers in endometrial cancer","volume":"18","author":"Lo","year":"1997","journal-title":"Tumour Biol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB123","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1002\/(SICI)1097-0142(19980501)82:9<1720::AID-CNCR19>3.0.CO;2-6","article-title":"CA 125\u00a0may not reflect disease status in patients with uterine serous carcinoma","volume":"82","author":"Price","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.biopha.2003.11.003_BIB124","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s004320050336","article-title":"Serum CA-125 as a marker of disease activity in uterine papillary serous carcinoma","volume":"125","author":"Abramovich","year":"1999","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB125","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1136\/jcp.49.12.967","article-title":"Serum and tissue measurements of CA72-4 in patients with endometrial carcinoma","volume":"49","author":"Hareyama","year":"1996","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB126","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1159\/000227443","article-title":"Serum level of macrophage colony-stimulating factor as a marker for gynecologic malignancies","volume":"52","author":"Suzuki","year":"1995","journal-title":"Oncology"},{"key":"10.1016\/j.biopha.2003.11.003_BIB127","first-page":"272","article-title":"Immunoacid protein (IAP) as marker for cervical and endometrial carcinoma: alone and in comparison with CA125 and SCC","volume":"5","author":"Gadducci","year":"1992","journal-title":"Cancer J"},{"key":"10.1016\/j.biopha.2003.11.003_BIB128","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/00004347-199607000-00012","article-title":"Hepatoid adenocarcinoma of the endometrium associated with alpha-fetoprotein production","volume":"15","author":"Hoshida","year":"1996","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB129","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1046\/j.1440-1827.2000.01124.x","article-title":"Alpha-fetoprotein producing uterine corpus carcinoma: a hepatoid adenocarcinoma of the endometrium","volume":"50","author":"Toyoda","year":"2000","journal-title":"Pathol Int"},{"key":"10.1016\/j.biopha.2003.11.003_BIB130","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1006\/gyno.2001.6383","article-title":"An alpha-fetoprotein-producing hepatoid adenocarcinoma of the endometrium","volume":"83","author":"Adams","year":"2001","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB131","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1136\/ijgc-00009577-200103000-00011","article-title":"Investigation of women with endometrial carcinoma using serum vascular endothelial growth factor (VEGF) measurement","volume":"11","author":"Gornall","year":"2001","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.biopha.2003.11.003_BIB132","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1002\/1097-0142(197710)40:4<1621::AID-CNCR2820400435>3.0.CO;2-I","article-title":"Radioimmunoassay for tumor antigen of human cervical squamous cell carcinoma","volume":"40","author":"Kato","year":"1977","journal-title":"Cancer"},{"key":"10.1016\/j.biopha.2003.11.003_BIB133","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1002\/1097-0142(19841015)54:8<1544::AID-CNCR2820540813>3.0.CO;2-B","article-title":"Tumor-antigen TA-4 in the detection of recurrence in cervical squamous cell carcinoma","volume":"54","author":"Kato","year":"1984","journal-title":"Cancer"},{"key":"10.1016\/j.biopha.2003.11.003_BIB134","first-page":"241","article-title":"The prognostic relevance of pretreatment serum immunosuppressive acidic protein (IAP) in patients with squamous cell carcinoma of the uterine cervix: a comparison with squamous cell carcinoma antigen (SCC)","volume":"7","author":"Gadducci","year":"1994","journal-title":"Cancer J"},{"key":"10.1016\/j.biopha.2003.11.003_BIB135","first-page":"1393","article-title":"Determination of serum levels of different cytokeratins in patients with uterine malignancies","volume":"14","author":"Ferdeghini","year":"1994","journal-title":"Anticancer Res"},{"key":"10.1016\/j.biopha.2003.11.003_BIB136","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1002\/1097-0142(19941101)74:9<2497::AID-CNCR2820740917>3.0.CO;2-L","article-title":"Serum level of squamous cell carcinoma antigen and tumor size are useful to identify preoperatively patients at high risk of cervical cancer","volume":"74","author":"Chou","year":"1994","journal-title":"Cancer"},{"key":"10.1016\/j.biopha.2003.11.003_BIB137","first-page":"512","article-title":"Prognostic significance of serum tumour markers in carcinoma of the cervix","volume":"17","author":"Ngan","year":"1996","journal-title":"Eur J Gynaecol Oncol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB138","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1006\/gyno.1996.4581","article-title":"Improvement of clinical staging in cervical cancer with serum squamous cell cervical carcinoma antigen and CA 125\u00a0determinations","volume":"64","author":"Massuger","year":"1997","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB139","first-page":"829","article-title":"Clinical evaluation of serum and immunohistological expression of SCC and CA19-9 in radiation therapy for cervical cancer","volume":"19","author":"Abe","year":"1999","journal-title":"Anticancer Res"},{"key":"10.1016\/j.biopha.2003.11.003_BIB140","first-page":"5113","article-title":"The impact of squamous cell carcinoma (SCC) antigen in the follow-up after radiotherapy in patients with cervical cancer","volume":"20","author":"Micke","year":"2000","journal-title":"Anticancer Res"},{"key":"10.1016\/j.biopha.2003.11.003_BIB141","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0360-3016(01)01805-3","article-title":"Serum squamous cell carcinoma antigen and CYFRA 21-1 in cervical cancer treatment","volume":"52","author":"Pras","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.biopha.2003.11.003_BIB142","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1200\/JCO.1996.14.1.111","article-title":"Pretreatment serum squamous cell carcinoma antigen: a newly identified prognostic factor in early-stage cervical carcinoma","volume":"14","author":"Duk","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB143","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/0959-8049(95)00515-3","article-title":"Multiple tumour marker assays in advanced cervical cancer: relationship to chemotherapy response and clinical outcome","volume":"32A","author":"Scambia","year":"1996","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.biopha.2003.11.003_BIB144","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1006\/gyno.1996.4589","article-title":"Prognostic significance of pre-treatment squamous cell carcinoma antigen and carcinoembryonic antigen in squamous cell carcinoma of the uterine cervix","volume":"64","author":"Bae","year":"1997","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB145","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/S0360-3016(98)00147-3","article-title":"The prognostic significance of pre- and posttreatment SCC levels in patients with squamous cell carcinoma of the cervix treated by radiotherapy","volume":"41","author":"Hong","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.biopha.2003.11.003_BIB146","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1006\/gyno.2000.5732","article-title":"Can initial serum cyfra 21-1, SCC antigen, and TPA levels in squamous cell cervical cancer predict lymph node metastases or prognosis?","volume":"77","author":"Gaarenstroom","year":"2000","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB147","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1034\/j.1600-0412.2002.810513.x","article-title":"Preoperative serum SCC, CA125, and CA19-9 levels and lymph node status in squamous cell carcinoma of the uterine cervix","volume":"81","author":"Takeda","year":"2002","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.biopha.2003.11.003_BIB148","first-page":"17","article-title":"Both TPA and SCC-Ag levels are prognostic even in high-risk stage Ib\u2013IIa cervical carcinoma as determined by a stratification analysis","volume":"23","author":"Yuan","year":"2002","journal-title":"Eur J Gynaecol Oncol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB149","first-page":"781","article-title":"Assessment of cervical cancer radioresponse by serum squamous cell carcinoma antigen and magnetic resonance imaging","volume":"100","author":"Ohara","year":"2002","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB150","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1006\/gyno.1998.4939","article-title":"The value of squamous cell carcinoma antigen as a predictor of nodal metastasis in cervical cancer","volume":"68","author":"Takeshima","year":"1998","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB151","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1159\/000030044","article-title":"The clinical value of squamous cell carcinoma antigen in cancer of the uterine cervix","volume":"19","author":"de Bruijn","year":"1998","journal-title":"Tumour Biol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB152","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1016\/S0959-8049(02)00159-4","article-title":"SCC antigen in the serum as an independent prognostic factor in operable squamous cell carcinoma of the cervix","volume":"38","author":"Strauss","year":"2002","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.biopha.2003.11.003_BIB153","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/00000421-199408000-00005","article-title":"Squamous cell carcinoma antigen, tumor-associated trypsin inhibitor, and carcinoembryonic antigen for monitoring cervical cancer","volume":"17","author":"Pectasides","year":"1994","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB154","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1200\/JCO.2001.19.19.3960","article-title":"Clinical value of routine serum squamous cell carcinoma antigen in follow-up of patients with early-stage cervical cancer","volume":"19","author":"Esajas","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB155","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1159\/000030035","article-title":"Tumour markers and their prognostic values in adenocarcinoma of the cervix","volume":"19","author":"Ngan","year":"1998","journal-title":"Tumour Biol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB156","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1007\/s004320050352","article-title":"Serum CYFRA 21-1 in cervical cancer patients treated with radiation therapy","volume":"126","author":"Suzuki","year":"2000","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB157","first-page":"27","article-title":"Study of a new tumor marker, CYFRA 21-1, in squamous cell carcinoma of the cervix, and comparison with squamous cell carcinoma antigen","volume":"43","author":"Tsai","year":"1996","journal-title":"Neoplasma"},{"key":"10.1016\/j.biopha.2003.11.003_BIB158","first-page":"2329","article-title":"Cyfra 21-1 in monitoring cervical cancer: a comparison with tissue polypeptide antigen and squamous cell carcinoma antigen","volume":"17","author":"Bonfrer","year":"1997","journal-title":"Anticancer Res"},{"key":"10.1016\/j.biopha.2003.11.003_BIB159","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/bjc.1995.543","article-title":"Serum tumour markers in carcinoma of the uterine cervix and outcome following radiotherapy","volume":"72","author":"Sproston","year":"1995","journal-title":"Br J Cancer"},{"key":"10.1016\/j.biopha.2003.11.003_BIB160","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1006\/gyno.1995.1126","article-title":"Tumor antigens CA 19.9, CA 125, and CEA in carcinoma of the uterine cervix","volume":"57","author":"Borras","year":"1995","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB161","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S0046-8177(00)80004-0","article-title":"Increased carcinoembryonic antigen expression in cervical intraepithelial neoplasia grade 3\u00a0and in cervical squamous cell carcinoma","volume":"31","author":"Tendler","year":"2000","journal-title":"Hum Pathol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB162","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1159\/000030143","article-title":"Clinical value of tumor markers for early detection of recurrence in patients with cervical adenocarcinoma and adenosquamous carcinoma","volume":"21","author":"Tabata","year":"2000","journal-title":"Tumour Biol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB163","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/00001813-200108000-00010","article-title":"A case of glassy cell carcinoma of the uterine cervix effectively responding to chemotherapy with paclitaxel and carboplatin","volume":"12","author":"Hirashima","year":"2001","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.biopha.2003.11.003_BIB164","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1006\/gyno.2001.6517","article-title":"Serum vascular endothelial growth factor and serum leptin in patients with cervical cancer","volume":"85","author":"Lebrecht","year":"2002","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.biopha.2003.11.003_BIB165","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1159\/000055352","article-title":"Clinical value of thymidine kinase in patients with cervical carcinoma","volume":"61","author":"Fujiwaki","year":"2001","journal-title":"Oncology"},{"key":"10.1016\/j.biopha.2003.11.003_BIB166","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/jnci\/93.19.1437","article-title":"Future for ovarian cancer screening: novel markers from emerging technologies of transcriptional profiling and proteomics","volume":"93","author":"Mills","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.biopha.2003.11.003_BIB167","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/1615-9861(200201)2:1<76::AID-PROT76>3.0.CO;2-O","article-title":"Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer","volume":"2","author":"Brown Jones","year":"2002","journal-title":"Proteomics"},{"key":"10.1016\/j.biopha.2003.11.003_BIB168","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/35049567","article-title":"Molecular profiling of human cancer","volume":"1","author":"Liotta","year":"2000","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.biopha.2003.11.003_BIB169","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2165\/00066982-200005040-00008","article-title":"Laser capture microdissection: beyond functional genomics to proteomics","volume":"5","author":"Simone","year":"2000","journal-title":"Mol Diagn"},{"key":"10.1016\/j.biopha.2003.11.003_BIB170","first-page":"69","article-title":"Cancer proteomics: from biomarker discovery to signal pathway profiling","volume":"7","author":"Bichsel","year":"2001","journal-title":"Cancer J"},{"key":"10.1016\/j.biopha.2003.11.003_BIB171","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(02)07746-2","article-title":"Use of proteomic patterns to identify ovarian cancer","volume":"359","author":"Petricoin","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2003.11.003_BIB172","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.5858\/2002-126-1518-PATTMD","article-title":"Proteomic approaches to tumor marker discovery","volume":"126","author":"Rai","year":"2002","journal-title":"Arch Pathol Lab Med"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332203001902?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332203001902?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T10:30:37Z","timestamp":1760092237000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332203001902"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,1]]},"references-count":172,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,1]]}},"alternative-id":["S0753332203001902"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2003.11.003","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2004,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum tumor markers in the management of ovarian, endometrial and cervical cancer","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2003.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"converted-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2003 \u00c9ditions scientifiques et m\u00e9dicales Elsevier SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}